# Tasly Pharmaceutical Group Co., Ltd trials: 32 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 32 trials with Tasly Pharmaceutical Group Co., Ltd as lead sponsor, 14 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Tasly Pharmaceutical Group Co., Ltd: 32 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/tasly-pharmaceutical-group-co-ltd

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 32
- Recruiting or not yet: 14
- Read on: November 19, 2026

## Trials

The 25 newest of 32, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| July 7, 2026 | NCT07687186 | Qishen Yiqi Dripping Pills in Treatment of Chronic Heart FailUre | Tasly Pharmaceutical Group Co., Ltd | Phase 3 | Recruiting | Heart Failure | 636 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07687186) |
| April 7, 2026 | NCT07514065 | TSL2109 Capsules in Advanced Solid Tumor Patients: Safety, Tolerability, PK and Preliminary Efficacy | Tasly Pharmaceutical Group Co., Ltd | Phase 1 | Recruiting | Metastatic Castration-Resistant Prostate Cancer Patients | 78 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07514065) |
| March 20, 2026 | NCT07485595 | A Study of the Effectiveness and Safety of JS1-1-01 Tablet in Patients With Moderate to Severe Depression | Tasly Pharmaceutical Group Co., Ltd | Phase 2/3 | Not yet recruiting | Depression | 180 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07485595) |
| January 28, 2026 | NCT07371624 | A Study of B2065 in Patients With Acute Ischemic Stroke | Tasly Pharmaceutical Group Co., Ltd | Phase 1/2 | Recruiting | Acute Ischemic Stroke | 54 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07371624) |
| January 6, 2026 | NCT07318818 | A Clinical Trial of P134 Cells in Recurrent Glioblastoma | Tasly Pharmaceutical Group Co., Ltd | Phase 1/2 | Recruiting | Recurrent Glioblastoma IDH Wildtype | 26 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07318818) |
| December 8, 2025 | NCT07269769 | A Clinical Trial Evaluating the Efficacy and Safety of Sanhuang Jingshiming Pills in the Treatment of nAMD | Tasly Pharmaceutical Group Co., Ltd | Phase 3 | Not yet recruiting | AMD | 450 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07269769) |
| December 4, 2025 | NCT07265349 | A Phase I/II Clinical Trial of Intramyocardial Injection of HucMSCs for the Treatment of Chronic Heart Failure | Tasly Pharmaceutical Group Co., Ltd | Phase 1/2 | Recruiting | Coronary Artery Bypass Grafting (CABG), Chronic Heart Failure, Chronic Ischemic Cardiomyopathy | 51 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07265349) |
| January 14, 2025 | NCT06773117 | Phase III Trial of Susu Zhike Granules in Children With Cold-cough Syndrome for Acute Cough Treatment | Tasly Pharmaceutical Group Co., Ltd | Phase 3 | Not yet recruiting | Cough | 360 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06773117) |
| December 31, 2024 | NCT06753890 | Efficacy and Safety of Changkang Granules in the Treatment of Irritable Bowel Syndrome With Predominant Diarrhea (Liver qi Affecting the... | Tasly Pharmaceutical Group Co., Ltd | Phase 3 | Not yet recruiting | Diarrhea-predominant Irritable Boewl Syndrome | 520 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06753890) |
| November 20, 2024 | NCT06697886 | A Study of the Efficacy and Safety of Antiwei Granules in the Treatment of Common Cold | Tasly Pharmaceutical Group Co., Ltd | Phase 3 | Recruiting | Common Cold | 480 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06697886) |
| November 20, 2024 | NCT06696261 | A Study of Lianxiaxiaopi Granules in the Treatment of Postprandial Distress Syndrome | Tasly Pharmaceutical Group Co., Ltd | Phase 3 | Recruiting | Postprandial Distress Syndrome | 342 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06696261) |
| November 13, 2024 | NCT06685978 | Efficacy and Safety of Xiangjurupining Capsule for Hyperplasia of Mammary Glands | Tasly Pharmaceutical Group Co., Ltd | Phase 3 | Recruiting | Hyperplasia of Mammary Glands | 430 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06685978) |
| November 1, 2024 | NCT06669169 | Efficacy and Safety of Jia Shen Tablets in Chronic Heart Failure | Tasly Pharmaceutical Group Co., Ltd | Phase 2 | Not yet recruiting | Heart Failure | 288 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06669169) |
| April 4, 2024 | NCT06348498 | Pharmacokinetic and Pharmacodynamic of Jia Shen Tablets in Chronic Heart Failure | Tasly Pharmaceutical Group Co., Ltd | Phase 1 | Unknown | Heart Failure | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06348498) |
| February 14, 2024 | NCT06259526 | A Study of the Effectiveness and Safety of JS1-1-01 in Patients With Moderate to Severe Depression | Tasly Pharmaceutical Group Co., Ltd | Phase 2 | Completed | Depression | 267 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06259526) |
| February 2, 2024 | NCT06238687 | A Study of STRO-002 in Chinese Adults With Epithelial Ovarian Cancer and Other Advanced Malignant Solid Tumors | Tasly Pharmaceutical Group Co., Ltd | Phase 1/2 | Completed | Neoplasm Malignant | 19 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06238687) |
| October 5, 2023 | NCT06068478 | A Study to Evaluate Efficacy and Safety of Qingzhu Granules in the Treatment of Acute Gouty Arthritis | Tasly Pharmaceutical Group Co., Ltd | Phase 3 | Completed | Gouty Arthritis | 472 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06068478) |
| October 5, 2023 | NCT06068465 | A Study of the Safety and Efficacy of Pimavanserin in Patients With Parkinson's Disease Psychosis | Tasly Pharmaceutical Group Co., Ltd | Phase 3 | Completed | Parkinson's Disease Psychosis | 248 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06068465) |
| September 28, 2023 | NCT06058546 | Efficacy and Safety of Jiuweihuaban Pill for Treating Plaque Psoriasis | Tasly Pharmaceutical Group Co., Ltd | Phase 2 | Unknown | Plaque Psoriasis | 180 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06058546) |
| August 23, 2023 | NCT06006689 | Efficacy and Safety of QiShen YiQi Dripping Pills in the Treatment of Diabetic Kidney Disease (Syndrome of Qi Deficiency With Blood Stasis) | Tasly Pharmaceutical Group Co., Ltd | Phase 2 | Completed | Diabetic Kidney Disease | 228 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06006689) |
| August 21, 2023 | NCT06000956 | A Study of Comparing Overall Improvement of Patients With Spondyloarthritis Treated With Jitongning Tablets and Placebo | Tasly Pharmaceutical Group Co., Ltd | Phase 3 | Recruiting | Ankylosing Spondylitis | 408 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06000956) |
| December 19, 2022 | NCT05656274 | A Study of the Safety,Tolerability,and Pharmacokinetics of Multiple-Ascending Dose JS1-1-01 in Healty Subjects. | Tasly Pharmaceutical Group Co., Ltd | Phase 1 | Completed | Healthy Volunteers | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05656274) |
| December 1, 2022 | NCT05632861 | HuHuangLianzonggan Capsule in Subjects With Nonalcoholic Steatohepatitis: a Phase 2 tRial(HHL-HEPAR) | Tasly Pharmaceutical Group Co., Ltd | Phase 2 | Unknown | NASH | 76 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05632861) |
| July 30, 2021 | NCT04983043 | Efficacy and Safety of QiShen YiQi Dripping Pills in Chronic Heart Failure | Tasly Pharmaceutical Group Co., Ltd | Phase 2 | Completed | Chronic Heart Failure With Reduced Ejection Fraction | 228 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04983043) |
| June 30, 2021 | NCT04944706 | Efficacy and Safety of Qishenyiqi Dripping Pills for Treating Chronic Heart Failure With Preserved Ejection Fraction | Tasly Pharmaceutical Group Co., Ltd | Phase 2 | Completed | Chronic Heart Failure With Preserved Ejection Fraction | 225 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04944706) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 5 |
| Phase 1/2 | 4 |
| Phase 2 | 12 |
| Phase 2/3 | 1 |
| Phase 3 | 10 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 15 |
| Recruiting | 9 |
| Not yet recruiting | 5 |
| Unknown | 3 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Heart Failure | 3 |
| Cough | 2 |
| Depression | 2 |
| Spondylarthritis | 1 |
| Macular Degeneration | 1 |
| Diabetic Nephropathies | 1 |
| Spondylitis, Ankylosing | 1 |
| Ischemic Stroke | 1 |
| Common Cold | 1 |
| Arthritis, Gouty | 1 |
| Neoplasms | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Pharmaceutical companies in the United States](https://specstream.ai/data/businesses/pharmaceutical-companies/united-states)
- [Executive search firms in the United States](https://specstream.ai/data/businesses/executive-search-firms/united-states)
- [Neuropathology practices in the United States](https://specstream.ai/data/businesses/neuropathology-practices/united-states)
- [Translation companies in the United States](https://specstream.ai/data/businesses/translation-companies/united-states)
- [Chinese restaurants in the United States](https://specstream.ai/data/businesses/chinese-restaurants/united-states)
- [Immigration law firms in the United States](https://specstream.ai/data/businesses/immigration-law-firms/united-states)
